Live Breaking News & Updates on Crystal Quast|Page 6
Stay updated with breaking news from Crystal quast. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vancouver, British Columbia (Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on ....
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc. Vancouver, British Columbia (Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ( Entheon or the Company ) is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. ( HaluGen ), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual s reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common shares in the capital of HaluGen (the HaluGen Shares ) from the shareholders of HaluGen (the HaluGen Shareholders ) pursuant to a share exchange agreement among the Company, HaluGen and the HaluGen Shareholders, resulting in HaluGen becoming a wholly-owned subsidiary of Entheon (the ....
Vancouver, British Columbia (Newsfile Corp. - January 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic ....
Entheon Biomedical Corp.: Entheon Biomedical Announces Private Placement Entheon or the Company ) announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the Units ) at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200,247.75 (the Placement ). This placement is fully subscribed by strategic investors and is expected to close on December 23rd. Each Unit will consist of one common share in the capital of the Company (a Share ) and one-half of one non-transferable share purchase warrant. Each whole Warrant (a Warrant ) will be exercisable to acquire one additional Share at an exercise price of CDN$1.00 per Share for a period of 24 months from the date of issuance, subject to accelerated expiry. ....
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs - Completion of Initial DMT Research Drug Batch and Exercise of Warrants Vancouver Canada based Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement with Psygen Labs Inc. Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances (“ DMT”) for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency (EMA) regulatory framework. On November 27, 2020, Psygen successfully completed the production of a non-GMP DMT research batch for delivery to the Company’s Contract Research Organization, CHDR’s partner pharmacy. The non-GMP DMT research batch will be shipped to CHDR upon receipt of Psygen� ....